@brendonneuen
Brendon Neuen
@brendonneuen
3 years
An incredible breakthrough & great news for our patients - the first ever treatment proven to reduce hospitalized heart failure or CV death in people with heart failure with preserved ejection fraction Results being presented next month at #ESC2021
Tweet card media
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only...

/PRNewswire/ -- The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance® (empagliflozin) as the first and only therapy to...

www.prnewswire.com
5
21
71

Replies

@hswapnil
Swapnil Hiremath @[email protected]
@hswapnil
3 years
@brendonneuen Didn’t sotagliflozin also show that? (Not the primary population etc etc)
Tweet card media
Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

The pooled analysis from SCORED/SOLOIST-WHF hints at a potential reduction in CV death, but more data are needed.

www.tctmd.com
1
0
0
@DrMuds
Sanj Mudaliar
@DrMuds
3 years
@brendonneuen Wow. Even I know this is a big deal.
0
0
3
@lenard_jakub
Jakub Lenard
@lenard_jakub
3 years
@brendonneuen Very interesting. How much longer are patients likely to live? Thanks
0
0
0
@PD_Perls
Jeff Perl
@PD_Perls
3 years
@brendonneuen Ironically was just wondering when HEFPEF data will emerge !
0
0
1
@KostaBrooks
Kostas Brooks BMed MD
@KostaBrooks
3 years
@brendonneuen What a great study! Congrats
0
0
0